Previous 10 | Next 10 |
Natera Announces Results of Large, Multi-Center Clinical Experience Study Showing Excellent Positive Predictive Value of the Prospera™ Kidney Test PR Newswire AUSTIN, Texas , Feb. 17, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in...
Landmark CIRCULATE-Japan Study Shows Natera's Signatera™ MRD Test is Predictive of Chemotherapy Benefit in Colorectal Cancer Analysis of 1,000+ patients, with 12 months mean follow up, demonstrates clinical utility of Signatera for informing post-surgical treatment decisi...
Blinded, prospective, multi-site trial shows the most common microdeletion can be detected non-invasively with a low false positive rate Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced the publication of the landmark...
Natera to Present Latest Signatera™ MRD Data in Colorectal and Pancreatic Cancers at the ASCO GI Symposium 2022, and Host Special Investor Call Oral presentations to include largest analysis to date from the prospective CIRCULATE-Japan study and results from first study s...
Dr. Alexey Aleshin to take on new role as GM of early cancer detection at Natera Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced its expansion into the early cancer detection (ECD) market to advance the companyȁ...
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA) on behalf of Natera stockholders. Our investigation concerns whether Natera...
Natera to Webcast Live Presentation at the 40th Annual J.P. Morgan Healthcare Conference PR Newswire AUSTIN, Texas , Jan. 4, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced that ...
Signatera™ Wins Fierce Life Sciences Innovation Award Natera's personalized MRD test selected as winner in the Medical Device Innovation category PR Newswire AUSTIN, Texas , Jan. 3, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in ...
Look for surprise values in underpriced stocks. Not the story issues being bally-hooed by touts and the media – everyone knows them. The hidden values are ones found by experienced professional researchers who know the details of industry group issues and their special strength...
Natera Presents Latest Signatera™ MRD Data in Breast Cancer at SABCS 2021 PR Newswire AUSTIN, Texas , Dec. 9, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced its latest fin...
News, Short Squeeze, Breakout and More Instantly...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...